The roadmap defines WHO’ work on medicine providing a comprehensive ground plan for WHO’ work during the period of 2019- 2023.
Oxfam urges the WHO to emphasise the following points:
1. Aligning the milestones on intellectual property with the recommendations of the Global Strategy and Plan of Action on IP and innovation;
2. Integrating relevant recommendations from the report of the High Level Panel on human rights and access to medicines;
3. Proactively promoting the use of the flexibilities enshrined in the Trade-Related Aspects of Intellectual Property Rights agreement (TRIPS);
4. Exploring incentives for biomedical innovation based on delinking financing of R&D from the price of resulting products;
5. Ensuring transparency across the medicine chain starting from the cost of R&D, the results of clinical trials and the prices of medicines in order to make effective medicines and health technologies affordable for health systems.
Oxfam urges member states to provide strong political support to recommend the roadmap for WHA approval. Member states also need to ensure that the roadmap is fully funded in order for the WHO to be able to support countries to scale up access to affordable quality medicines, vaccines and health technologies.
Achieving Universal Health Coverage depends on access to affordable quality medicines. The implementation of the WHO roadmap is critical for countries to achieve UHC and the SDGs targets on access to medicines.